{"id":46118,"date":"2025-11-08T10:33:52","date_gmt":"2025-11-08T02:33:52","guid":{"rendered":"https:\/\/flcube.com\/?p=46118"},"modified":"2025-11-08T10:33:53","modified_gmt":"2025-11-08T02:33:53","slug":"viatris-posts-q3-2025-revenue-dip-highlights-emerging%e2%80%91market-branded-growth-and-aculys-pharma-acquisition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46118","title":{"rendered":"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">U.S.\u2011based <strong>Viatris Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/VTRS:NASDAQ\">NASDAQ: VTRS<\/a>) released its third\u2011quarter 2025 earnings, showing a <strong>2\u202f% year\u2011over\u2011year (YOY) decline<\/strong> in total revenue to <strong>$3.76\u202fbillion<\/strong>. The figures are presented on an <strong>operational basis<\/strong> (currency\u2011neutral). Over the first nine months, revenue fell <strong>6\u202f% YOY<\/strong> to <strong>$10.6\u202fbillion<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-revenue-breakdown-branded-vs-generics\">Revenue Breakdown \u2013 Branded vs. Generics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Q3\u202f2025 Revenue<\/th><th>Q3\u202f2025 YoY Growth<\/th><th>9M\u202f2025 Revenue<\/th><th>9M\u202f2025 YoY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Branded portfolio<\/strong><\/td><td><strong>$2.44\u202fbn<\/strong><\/td><td><strong>+1\u202f%<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Generics<\/strong><\/td><td><strong>$1.31\u202fbn<\/strong><\/td><td><strong>\u20116\u202f%<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><em>The branded segment\u2019s modest gain was driven by strong demand in <strong>Emerging Markets<\/strong> and <strong>Greater China<\/strong>.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regional-performance\">Regional Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Q3\u202f2025 Revenue (USD\u202fmn)<\/th><th>Q3\u202f2025 Growth<\/th><th>9M\u202f2025 Revenue (USD\u202fmn)<\/th><th>9M\u202f2025 Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Developed Markets<\/strong><\/td><td>2,255.6<\/td><td><strong>\u20115\u202f%<\/strong><\/td><td>6,266.6<\/td><td><strong>\u20119\u202f%<\/strong><\/td><\/tr><tr><td><strong>Emerging Markets<\/strong><\/td><td>570.4<\/td><td><strong>+7\u202f%<\/strong><\/td><td>1,645.4<\/td><td><strong>\u20114\u202f%<\/strong><\/td><\/tr><tr><td><strong>JANZ<\/strong> (Japan, Australia, New\u202fZealand)<\/td><td>306.3<\/td><td><strong>\u201110\u202f%<\/strong><\/td><td>888.1<\/td><td><strong>\u201111\u202f%<\/strong><\/td><\/tr><tr><td><strong>Greater China<\/strong><\/td><td>615.2<\/td><td><strong>+9\u202f%<\/strong><\/td><td>1,759.6<\/td><td><strong>+8\u202f%<\/strong><\/td><\/tr><tr><td><strong>Total<\/strong><\/td><td><strong>3,759.9<\/strong><\/td><td><strong>\u20112\u202f%<\/strong><\/td><td><strong>10,596.3<\/strong><\/td><td><strong>\u20116\u202f%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Source: Viatris internal reporting.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-highlights\">Strategic Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aculys Pharma acquisition<\/strong> \u2013 announced in Q3, giving Viatris <strong>exclusive development and commercialization rights in Japan<\/strong> to <strong>pitolisant<\/strong>, a Phase\u202fIII selective\/inverse H3\u2011receptor agonist. Two NDAs are slated for filing in Japan by year\u2011end for:<\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Excessive daytime sleepiness (EDS) or cataplexy in adult narcolepsy<\/strong><\/li>\n\n\n\n<li><strong>EDS associated with obstructive sleep\u2011apnea syndrome<\/strong><\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Spydia Nasal Spray (diazepam)<\/strong> \u2013 Viatris now controls this product in Japan and selected Southeast\u2011Asian markets after the June\u202f2025 Japanese approval for <strong>status epilepticus<\/strong>.<\/li>\n\n\n\n<li><strong>Emerging\u2011Market momentum<\/strong> \u2013 Branded sales grew <strong>7\u202f%<\/strong> in the quarter, outpacing all other regions, underscoring Viatris\u2019s execution of its \u201cEmerging\u2011Market growth engine.\u201d<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-analyst-reaction\">Analyst Reaction<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Equity movement:<\/strong> Viatris shares edged <strong>up 0.8\u202f%<\/strong> in early trading, reflecting confidence that the <strong>Emerging\u2011Market upside<\/strong> will offset broader revenue softness.<\/li>\n\n\n\n<li><strong>Sell\u2011side outlook:<\/strong> Several brokerage houses upgraded Viatris to <strong>\u201cOutperform\u201d<\/strong> on the basis of the <strong>Aculys deal<\/strong> and the <strong>robust branded performance in Greater China<\/strong>, while maintaining a cautious view on the <strong>generics segment<\/strong> which remains under pressure.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements regarding Viatris\u2019s financial results, acquisition strategy and market outlook. Actual results may differ due to risks and uncertainties described in the company\u2019s most recent Form\u202f10\u2011K filing.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/Viatris-Reports-Third-Quarter-2025-Results-and-Updates-2025-Financial-Guidance.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance.\"><\/object><a id=\"wp-block-file--media-ba9a97bd-c483-4843-9c0e-1c8c63c83429\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/Viatris-Reports-Third-Quarter-2025-Results-and-Updates-2025-Financial-Guidance.pdf\">Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/Viatris-Reports-Third-Quarter-2025-Results-and-Updates-2025-Financial-Guidance.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ba9a97bd-c483-4843-9c0e-1c8c63c83429\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>U.S.\u2011based Viatris Inc. (NASDAQ: VTRS) released its third\u2011quarter 2025 earnings, showing a 2\u202f% year\u2011over\u2011year (YOY)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,1018,207],"class_list":["post-46118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nasdaq-vtrs","tag-viatris"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"U.S.\u2011based Viatris Inc. (NASDAQ: VTRS) released its third\u2011quarter 2025 earnings, showing a 2\u202f% year\u2011over\u2011year (YOY) decline in total revenue to $3.76\u202fbillion. The figures are presented on an operational basis (currency\u2011neutral). Over the first nine months, revenue fell 6\u202f% YOY to $10.6\u202fbillion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46118\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition\" \/>\n<meta property=\"og:description\" content=\"U.S.\u2011based Viatris Inc. (NASDAQ: VTRS) released its third\u2011quarter 2025 earnings, showing a 2\u202f% year\u2011over\u2011year (YOY) decline in total revenue to $3.76\u202fbillion. The figures are presented on an operational basis (currency\u2011neutral). Over the first nine months, revenue fell 6\u202f% YOY to $10.6\u202fbillion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46118\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-08T02:33:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-08T02:33:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0804.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition\",\"datePublished\":\"2025-11-08T02:33:52+00:00\",\"dateModified\":\"2025-11-08T02:33:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0804.webp\",\"keywords\":[\"Finanical Reports\",\"NASDAQ: VTRS\",\"Viatris\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46118#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46118\",\"name\":\"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0804.webp\",\"datePublished\":\"2025-11-08T02:33:52+00:00\",\"dateModified\":\"2025-11-08T02:33:53+00:00\",\"description\":\"U.S.\u2011based Viatris Inc. (NASDAQ: VTRS) released its third\u2011quarter 2025 earnings, showing a 2\u202f% year\u2011over\u2011year (YOY) decline in total revenue to $3.76\u202fbillion. The figures are presented on an operational basis (currency\u2011neutral). Over the first nine months, revenue fell 6\u202f% YOY to $10.6\u202fbillion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46118\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0804.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0804.webp\",\"width\":1080,\"height\":608,\"caption\":\"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46118#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition - Insight, China&#039;s Pharmaceutical Industry","description":"U.S.\u2011based Viatris Inc. (NASDAQ: VTRS) released its third\u2011quarter 2025 earnings, showing a 2\u202f% year\u2011over\u2011year (YOY) decline in total revenue to $3.76\u202fbillion. The figures are presented on an operational basis (currency\u2011neutral). Over the first nine months, revenue fell 6\u202f% YOY to $10.6\u202fbillion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46118","og_locale":"en_US","og_type":"article","og_title":"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition","og_description":"U.S.\u2011based Viatris Inc. (NASDAQ: VTRS) released its third\u2011quarter 2025 earnings, showing a 2\u202f% year\u2011over\u2011year (YOY) decline in total revenue to $3.76\u202fbillion. The figures are presented on an operational basis (currency\u2011neutral). Over the first nine months, revenue fell 6\u202f% YOY to $10.6\u202fbillion.","og_url":"https:\/\/flcube.com\/?p=46118","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-08T02:33:52+00:00","article_modified_time":"2025-11-08T02:33:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0804.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46118#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46118"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition","datePublished":"2025-11-08T02:33:52+00:00","dateModified":"2025-11-08T02:33:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46118"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46118#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0804.webp","keywords":["Finanical Reports","NASDAQ: VTRS","Viatris"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46118#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46118","url":"https:\/\/flcube.com\/?p=46118","name":"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46118#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46118#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0804.webp","datePublished":"2025-11-08T02:33:52+00:00","dateModified":"2025-11-08T02:33:53+00:00","description":"U.S.\u2011based Viatris Inc. (NASDAQ: VTRS) released its third\u2011quarter 2025 earnings, showing a 2\u202f% year\u2011over\u2011year (YOY) decline in total revenue to $3.76\u202fbillion. The figures are presented on an operational basis (currency\u2011neutral). Over the first nine months, revenue fell 6\u202f% YOY to $10.6\u202fbillion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46118#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46118"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46118#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0804.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0804.webp","width":1080,"height":608,"caption":"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46118#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Viatris Posts Q3\u202f2025 Revenue Dip, Highlights Emerging\u2011Market Branded Growth and Aculys Pharma Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0804.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46118"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46118\/revisions"}],"predecessor-version":[{"id":46121,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46118\/revisions\/46121"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46120"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}